ULBP3 and breast carcinoma: Kruijf et al. [45] studied 677 breast cancer patients from 1985 to 1994 to verify the expression of NKG2D ligands (NKG2DL) using immunohistochemical staining and they found that NKG2DL was frequently expressed by tumors (ULBP1, 90% of the cases; ULBP2, 99%; ULBP3, 100%; ULBP4, 26%; ULBP5, 90%).